Evidence map›Paper›PMID 33038770›Full record

ArticleEBioMedicine2020

A prognostic gene expression signature for oropharyngeal squamous cell carcinoma.

Xinyi Liu, Ping Liu, Rebecca D Chernock, Krystle A Lang Kuhs, James S Lewis, Jingqin Luo, Hiram A Gay, Wade L Thorstad, Xiaowei Wang

Open access · goldAbstract read
In one paragraph

Article in EBioMedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Noncanonical HPV carcinogenesis drives radiosensitization of head and neck tumors.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. The Architecture of a Precision Oncology Platform.Advances in experimental medicine and biology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Xinyi LiuDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA.
Ping LiuDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA.
Rebecca D ChernockDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Krystle A Lang KuhsDepartment of Otolaryngology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
James S LewisDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Jingqin LuoDepartment of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Hiram A GayDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA.
Wade L ThorstadDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA.
Xiaowei WangDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA. Electronic address: xwang317@uic.edu.
Washington University in St. Louis · USVanderbilt University Medical Center · US

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI AIMEE S JAMES · 2001 to 2026
$128.0M
Vanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9M
COMBINED COMPUTATIONAL AND EXPERIMENTAL ANALYSES OF GENE REGULATION BY MICRORNAS.R01GM089784 · NIGMS · WASHINGTON UNIVERSITY · PI WANG, XIAOWEI · 2010 to 2019
$2.8M
MICRORNA BIOMARKERS FOR OROPHARYNGEAL CANCERR01DE026471 · NIDCR · WASHINGTON UNIVERSITY · PI WANG, XIAOWEI · 2017 to 2021
$2.2M
Human Papillomavirus-Specific Biomarkers for the Prediction of Oropharyngeal Cancer RecurrenceK07CA218247 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KUHS, KRYSTLE A. · 2018 to 2021
$594k
NCI NIH HHS K07 CA218247NCI NIH HHS K12 CA090625NCI NIH HHS P30 CA091842NIDCR NIH HHS R01 DE026471NIGMS NIH HHS R01 GM089784
6 · The paper itself

Abstract

backgroundRobust prognostic stratification of patients with oropharyngeal squamous cell carcinoma (OPSCC) is important for developing individualized treatment plans. This study was conducted to develop and validate a clinically feasible prognostic classifier based on transcriptome-wide gene expression profiles.

methodsTumor tissues were collected from 208 OPSCC patients treated at Washington University in St. Louis and 130 OPSCC patients treated at Vanderbilt University, used for model training and validation, respectively. OPSCC patients (n = 70) from the TCGA cohort were also included for independent validation. Based on RNA-seq profiling data, Cox proportional hazards regression analysis was performed to identify genes associated with disease outcomes. Then, Lasso-penalized multivariate survival models were constructed to identify biomarker genes for developing a prognostic gene signature.

findingsA 60-gene signature was identified by RNA-seq profiling analysis. Computed risk score of the gene signature was significantly predictive of 5-year overall survival of the training cohort (Hazard ratio (HR) 28·32, P = 4·3E-41). Subgroup analysis stratified by HPV status revealed that the signature was prognostic in HPV-positive OPSCC patients (HR 30·55, P = 7·0E-37) and was independent of clinical features. Importantly, the gene signature was validated in two independent patient cohorts, including the TCGA cohort (HR 3·94, P = 0·0018) and the Vanderbilt cohort (HR 8·50, P = 5·7E-09) for overall survival.

interpretationThe prognostic gene signature is a robust tool for risk stratification of OPSCC patients. The signature remains prognostic among HPV-positive OPSCC patients.

fundingNational Institutes of Health.

Indexed as

Biomarkers, TumorGene Expression Regulation, NeoplasticTranscriptomeAdultAgedCell Line, TumorComputational BiologyDisease SusceptibilityFemaleGene Expression ProfilingHigh-Throughput Nucleotide SequencingHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm StagingBiomarkers, TumorGene signatureOropharyngeal cancerPrognosisRNA-seq

Identifiers

PMID33038770
PMCPMC7648117
OpenAlexW3092378804

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.